Trial intelligence / Profile preview

TRK-820 Soft Capsules for Intractable Pruritus in Chronic Liver Disease

jRCT2080221261Phase 3

Sponsor
Toray Industries
Start
Oct 2010
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial of nalfurafine in chronic liver disease (CLD) and pruritus (3 arms), sponsored by Toray Industries.

02

Drugs

nalfurafine
03

Conditions

chronic liver disease (CLD)pruritus

Beyond the preview

Go deeper on jRCT2080221261.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCT2080221261.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call